Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...
Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma Retrospective review of 33,850 molecularly profiled ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback